NMRC
“Sclera Cross-linking in the Experimental Rabbit Eye Model (NMRC/NIG/1049/2011)”. Dr Daphne Han; $ 199,097.00
“Diabetic Retinopathy: Arresting Diabetic Retinopathy and Improving Quality of Life - Identifying the factors influencing effective diabetic management and proposing a novel care model (NMRC/NIG/1047/2011)”. Dr Gavin Siew Wei Tan; $ 199,995.40
“A STUDY OF THE BIODYNAMIC, BIOMECHANICAL AND MOLECULAR PROPERTIES OF THE IRIS IN ANGLE CLOSURE DISEASE (NIG11nov026)”. Dr Narayanaswamy Arun Kumar; $199,914.00
“Iris and Choroidal Characteristics in Asian Eyes: Elucidating the Mechanism of Primary Angle Closure Glaucoma (NIG11may029)”. Dr Cheng Ching-Yu; $192,936.00
“Novel Retinal Imaging as a “Biomarker” to Identify Acute Coronary Syndrome in Low-risk Chest Pain Patients Presenting to the Emergency Department (NIG11may027)”. Dr Carol Cheung; $199,940.00
BMRC
“Angle Closure Glaucoma: Novel methods for Imaging, Risk Assessment and Screening (10/1/35/19/674)”. Prof Aung Tin; $ 1,679,183.00
“Does Genetic Variation in the CFH region of Age-Related Macular Degeneration patients allow Bacteria to trigger the Disease? (10/1/35/19/671)”. Prof Wong Tien Yin; $ 1,583,259.00
“Development of a diagnostic and prognostic model for primary open angle glaucoma (POAG) using genomic and endophenotypic constructs (10/1/35/19/675)”. Prof Eranga N Vithana; $ 1,576,747.00
“Innovations in tissue engineering of selective corneal cell layers for corneal transplantation (10/1/35/19/673)”. Prof Jodhbir S Mehta; $ 2,335,500.00
“Intelligent Meibography imaging for the assessment of Ocular Surface Inflammation (10/1/35/19/670)”. Prof Louis Tong; $ 317,300.00
“Diabetic Retinopathy: novel methods in detection, pathogenesis and treatment (10/1/35/19/672)”. Prof Wong Tien Yin; $ 1,186,853.00
A*Star/Duke-NUS/MOH/Others
“Exploit Technologies Flagship Grant, The Development of the Branched Antimicrobial Peptides (BMAPs) Platform Technology as a Future Medicine, and Antimicrobial Agents (ETPL/10-S10FSH-0008)”. Prof Roger Beuerman; $2,429,900.00
“Genetic Markers of Asian Age-related Macular Degeneration (M2011068)”. Dr Belinda Kate Cornes; USD 94,561 Singhealth:
“Evaluation of a novel sensor for continuous intraocular pressure monitoring in glaucoma subjects (SHF/FG428P/2010)”. Dr Mani Baskaran; $146,278.63
“Evaluation of OsteoMesh Implant for Eyelid Reconstruction: Pilot Study (SHF/FG486S/2010)In Vivo Evaluation of VEGF and Antimicrobial Peptide Bound Titanium Substrates for a Keratoprosthesis Device (SHF/FG488S/2010)”. Dr Livia Teo; $ 22,065.35
“In Vivo Evaluation of VEGF and Antimicrobial Peptide Bound Titanium Substrates for a Keratoprosthesis Device (SHF/FG488S/2010)”. Dr Tan Xiao Wei; $ 49,550.00
“Cytoskeleton regulators in the control of corneal fibrosis (SHF/FG489S/2010)”. “Four-year follow up of a Singapore population screened for primary angle closure ( SHF/FG485S/2010)”. Dr Zhu Hong-Yuan; $ 49,997.00
“Four-year follow up of a Singapore population screened for primary angle closure ( SHF/FG485S/2010)”. Dr Arun Kumar Narayanaswamy; $ 49,000.00
“The Moorfields Motion Displacement Test: A new form of perimetry for detecting glaucomatous visual field changes, a pilot study in Singapore (SHF/FG429P/2010)”. Dr Su-Wei Alicia Claire How; $199,952.00
“The Immuno-genetics of Posner Schlossman syndrome with Ocular Cytomegalovirus (SHF/FG487S/2010)”. Dr Jay Siak Jyh Kuen; $ 50,000.00
“To examine the relationship between intraocular pressure, serum osmolality and choroidal thickness during the Water Drinking Test in patients with angle closure disease (SHF/FG484S/2010)”. Dr Monisha Esther Nongpiur; $ 49,300.00
Commercial
“A Prospective Multicenter clinical trial to evaluate the safety and effectiveness of the Acufocus TM Corneal Inlay ACI 7000PDT Implanted Intra-Stromally for Modified Monovision in Prebyopic subjects (ACU-P10-020B)”. Prof Jodhbir S Mehta; $ 278,170.82
“A Phase 1b/2a, Dose-escalation Study to Assess the Safety and Feasibility of a Single Intravitreal Injection of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects with Neovascular Age Related Macular Degeneration Undergoing Avastin/ Lucentis Therapy”. Prof Ian Yeo; $ 325,045.18
Subscribe to our mailing list to get the updates to your email inbox...
